Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study.-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study.

Published:2013-04-15 Issue: Volume: Page:
ISSN:
Container-title:Clinical Research
language:
Short-container-title:

Author:

Juric Dejan,Krop Ian,Ramanathan Ramesh K.,Xiao Jim,Sanabria Sandra,Wilson Timothy R.,Choi YounJeong,Parmar Hema,Hsu Jerry,Baselga Jose,Von Hoff Daniel D.

Publisher

American Association for Cancer Research

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overexpression of antiapoptotic gene products and resistance to trastuzumab treatment of breast cancer;Overcoming Cancers Resistant to HER-2 Antibodies;2024

2. Quatramer™ mediated co-delivery of PI3-Kδ/HDAC6 dual inhibitor augments the anti-cancer efficacy of Epirubicin in breast cancer;European Journal of Pharmaceutics and Biopharmaceutics;2022-10

3. PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives;Cancers;2022-04-26

4. The complex balance of PI3K inhibition;Annals of Oncology;2021-02

5. A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer;Breast Cancer Research;2018-09-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP